Burden of Medically Attended Diarrhea and Outpatient Clostridioides difficile Infection Among Persons in 2 Large Integrated Healthcare Settings, 2016-2021.

Autor: Tartof SY; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA., Schmidt MA; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.; Science Programs Department, Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA., Contreras R; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Angulo FJ; Vaccines, Antivirals, and Evidence Generation, Pfizer Inc, NewYork, New York, USA., Florea A; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Barreras JL; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Donald J; Science Programs Department, Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA., Zamparo J; Vaccines, Antivirals, and Evidence Generation, Pfizer Inc, NewYork, New York, USA., Grant DL; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA., Shuster E; Science Programs Department, Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA., Gonzalez E; Vaccines, Antivirals, and Evidence Generation, Pfizer Inc, NewYork, New York, USA., Kuntz JL; Science Programs Department, Kaiser Permanente Northwest Center for Health Research, Portland, Oregon, USA.

Publikováno v: Open forum infectious diseases [Open Forum Infect Dis] 2024 Jan 11; Vol. 11 (1), pp. ofad680. Date of Electronic Publication: 2024 Jan 11 (Print Publication: 2024).

Frequency of stool specimen collection and testing for Clostridioides difficile of hospitalized adults and long-term care facility residents with new-onset diarrhea in Louisville, Kentucky.

Autor: Angulo FJ; Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, 500 Arcola Road 4024 NE Alameda Street, Collegeville, PA 19426, USA. Electronic address: frederick.angulo@pfizer.com., Oliva SP; Center of Excellence for Research in Infectious Diseases (CERID), Division of Infectious Diseases, School of Medicine, University of Louisville, 501 East Broadway, Suite 100, Louisville, KY 40202, USA., Carrico R; Center of Excellence for Research in Infectious Diseases (CERID), Division of Infectious Diseases, School of Medicine, University of Louisville, 501 East Broadway, Suite 100, Louisville, KY 40202, USA., Furmanek S; Center of Excellence for Research in Infectious Diseases (CERID), Division of Infectious Diseases, School of Medicine, University of Louisville, 501 East Broadway, Suite 100, Louisville, KY 40202, USA; Norton Healthcare, Norton Infectious Diseases Institute, Louisville, KY 40202, USA., Zamparo J; Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, 500 Arcola Road 4024 NE Alameda Street, Collegeville, PA 19426, USA., Gonzalez E; Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, 500 Arcola Road 4024 NE Alameda Street, Collegeville, PA 19426, USA., Gray S; Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, 500 Arcola Road 4024 NE Alameda Street, Collegeville, PA 19426, USA., Ford KD; Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, 500 Arcola Road 4024 NE Alameda Street, Collegeville, PA 19426, USA., Swerdlow D; Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, 500 Arcola Road 4024 NE Alameda Street, Collegeville, PA 19426, USA; Beacon Epidemiology Associates, LLC, Phoenixville, PA 19460, USA., Moïsi JC; Medical Development and Scientific/Clinical Affairs, Pfizer Vaccines, 500 Arcola Road 4024 NE Alameda Street, Collegeville, PA 19426, USA., Ramirez J; Center of Excellence for Research in Infectious Diseases (CERID), Division of Infectious Diseases, School of Medicine, University of Louisville, 501 East Broadway, Suite 100, Louisville, KY 40202, USA; Norton Healthcare, Norton Infectious Diseases Institute, Louisville, KY 40202, USA.

Publikováno v: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2022 Jul; Vol. 120, pp. 196-200. Date of Electronic Publication: 2022 Apr 25.

A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.

Autor: Tatum, H., Thuluvath, P. J., Lawitz, E., Martorell, C., DeMicco, M., Cohen, S., Rustgi, V., Ravendhran, N., Ghalib, R., Hanson, J., Zamparo, J., Zhao, J., Cooney, E., Treitel, M., Hughes, E.

Publikováno v: Journal of Viral Hepatitis; Aug2015, Vol. 22 Issue 8, p658-664, 7p

Symptoms and Severity of COVID-19 in Patients with Immune-Mediated Inflammatory Diseases: Experience of a University Medical Center.

Autor: Schlosser, Tobias¹ (AUTHOR), Krasselt, Marco² (AUTHOR), Elsing, Louis¹ (AUTHOR), Hecker, Martin¹ (AUTHOR), Holler, Babett¹ (AUTHOR), Hoffmeister, Albrecht¹ (AUTHOR)

Publikováno v: Autoimmune Diseases (2090-0422). 3/27/2024, Vol. 2024, p1-11. 11p.

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.

Autor: Ahmad T; Duke Clinical Research Institute, Durham, NC., Yin P; Bristol-Myers Squibb, Wallingford, CT., Saffitz J; Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA., Pockros PJ; Scripps Clinic, La Jolla, CA., Lalezari J; Quest Clinical Research, San Francisco, CA., Shiffman M; Liver Institute of Virginia, Bon Secours Health System, Newport News, VA., Freilich B; Kansas City Gastroenterology & Hepatology Physicians Group, Kansas City, MO., Zamparo J; Bristol-Myers Squibb, Wallingford, CT., Brown K; Bristol-Myers Squibb, Wallingford, CT., Dimitrova D; Bristol-Myers Squibb, Hopewell, NJ., Kumar M; Bristol-Myers Squibb, Hopewell, NJ., Manion D; Bristol-Myers Squibb, Hopewell, NJ., Heath-Chiozzi M; Bristol-Myers Squibb, Wallingford, CT., Wolf R; Bristol-Myers Squibb, Lawrenceville, NJ., Hughes E; Bristol-Myers Squibb, Lawrenceville, NJ., Muir AJ; Duke Clinical Research Institute, Durham, NC., Hernandez AF; Duke Clinical Research Institute, Durham, NC.

Publikováno v: Hepatology (Baltimore, Md.) [Hepatology] 2015 Aug; Vol. 62 (2), pp. 409-16. Date of Electronic Publication: 2015 May 26.